Alvotech (ICE:ALVO)
Iceland
· Delayed Price · Currency is ISK 674.00
+64.00 (10.49%)
At close: Dec 5, 2025
Alvotech Employees
Alvotech had 1,012 employees as of December 31, 2024. The number of employees increased by 13 or 1.30% compared to the previous year.
Employees
1,012
Change (1Y)
13
Growth (1Y)
1.30%
Revenue / Employee
68.80M ISK
Profits / Employee
8.34M ISK
Market Cap
219.28B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,012 | 13 | 1.30% |
| Dec 31, 2023 | 999 | 82 | 8.94% |
| Dec 31, 2022 | 917 | 133 | 16.96% |
| Dec 31, 2021 | 784 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Marel | 7,500 |
| Íslandsbanki | 764 |
| Arion banki | 822 |
| Sildarvinnslan Hf. | 723 |
| Brim hf. | 694 |
| Hagar | 2,699 |
| Kvika banki | 270 |
| Festi | 1,352 |
Alvotech News
- 19 hours ago - ROSEN, LEADING INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO - Newsfile Corp
- 2 days ago - Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO - Business Wire
- 3 days ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - PRNewsWire
- 12 days ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - GlobeNewsWire
- 12 days ago - Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area - GlobeNewsWire
- 16 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO - PRNewsWire
- 16 days ago - Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 16 days ago - Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - GlobeNewsWire